Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tepilamide fumarate - Arbor Pharmaceuticals/Dr. Reddy's Laboratories

Drug Profile

Tepilamide fumarate - Arbor Pharmaceuticals/Dr. Reddy's Laboratories

Alternative Names: Methyl hydrogen fumarate prodrug - Arbor Pharmaceuticals; PPC 06; XP-23829

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XenoPort
  • Developer Dr Reddys Laboratories; XenoPort
  • Class Amides; Anti-inflammatories; Antipsoriatics; Esters; Fumarates; Small molecules
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Plaque psoriasis
  • Discontinued Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-II for Plaque psoriasis in USA (PO) (NCT03421197)
  • 30 Mar 2020 Dr. Reddy's Laboratories completes a phase II AFFIRM trial in Plaque psoriasis in USA (PO) (NCT03421197)
  • 10 Jun 2019 Topline efficacy and adverse events data from the phase II AFFIRM trial in Plaque psoriasis released by Dr. Reddy's Laboratories
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top